Abstract
Acerta Pharma is developing the Bruton's tyrosine kinase inhibitor acalabrutinib (Calquence(A (R))) for the treatment of various haematological and so......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
